Answer
Diarrhoea was very common (≥1 in 10), reported in 36% of patients with relapsed or refractory diffuse large B-cell lymphoma receiving tafasitamab plus lenalidomide in L-MIND; frequencies reflect all-cause adverse events, which may have causes other than treatment.
Sources for this answer
- MINJUVI 200 mg powder for concentrate for solution for infusionIncyte Biosciences UK Ltd · emc · SmPC §4.8 Undesirable effects · Version 13Document updated
Sources checked